Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01485588 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study for Age-Related Macular Degeneration
A Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Iconic Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT01485588: Completed Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Iconic Therapeutics.
NCT01485588 is a Phase 1 study of Neovascular Age-related Macular Degeneration that has completed, run by Iconic Therapeutics. The registered enrollment target is 18 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01485588, a Phase 1 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Iconic Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.
Primary Outcome
The Mean Change in Central Retinal Subfield Thickness as Measured by OCT is part of the evaluation on the safety and tolerability of single ascending doses of hI-con1 and to assist in determining the Maximum Tolerated Dose (MTD) that can be administered by intravitreal injection.
Conditions Studied
Interventions
- DRUG hI-con1™ 60µl
- DRUG hI-con1™ 150µl
- DRUG hI-con1™ 300µl
Study Locations (5)
Texas
- Retina Research Center - Austin
- Valley Retina Institute, PA - McAllen
Montana
- Rocky Mountain Eye Center, P.C. - Missoula
Oregon
- Retina & Vitreous Center of Southern Oregon, P.C. - Ashland
South Carolina
- Palmetto Retina Center - West Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT01485588 record still lists
NCT01485588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which hI-con1™ 60µl is the first listed.
NCT01485588 lists 5 locations in 4 states (Texas, Montana, Oregon).
Frequently Asked Questions
What is clinical trial NCT01485588 about?
NCT01485588 is a clinical study titled "Safety and Tolerability Study for Age-Related Macular Degeneration". Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.
What is the current status of trial NCT01485588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-12. Estimated completion is 2012-03.
What conditions does trial NCT01485588 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT01485588?
The interventions under investigation include: hI-con1™ 60µl (DRUG), hI-con1™ 150µl (DRUG), hI-con1™ 300µl (DRUG).
Who is sponsoring clinical trial NCT01485588?
This trial is sponsored by Iconic Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01485588 being conducted?
This trial has 5 study locations across Montana, Oregon, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01485588's enrollment target sits among peer trials
18 32nd of 33 higher than 2 of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
ACTIVE NOT RECRUITING · Phase 1
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
COMPLETED · Phase 1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia